Select year

2026 2025 2024 2023 2022 Earlier

shown/page

10

2024.07.23

NMPA Approves Phase III Clinical Trial Application for Chipscreen’s Class I Innovative Anti-Tumor Drug Chidamide in Colorectal Cancer Treatment
NMPA Approves Phase III Clinical Trial Application for Chipscreen’s Class I Innovative Anti-Tumor Drug Chidamide in Colorectal Cancer Treatment

2024.07.19

Chiglitazar Sodium (Bilessglu®) in Combination with Metformin Approved by NMPA for Type 2 Diabetes
Chiglitazar Sodium (Bilessglu®) in Combination with Metformin Approved by NMPA for Type 2 Diabetes

2024.06.08

Chipscreen Biosciences' Chidamide tablets designated as a breakthrough therapy for advanced colorectal cancer
Chipscreen Biosciences' Chidamide tablets designated as a breakthrough therapy for advanced colorectal cancer

2024.04.30

National Medical Products Administration (NMPA) Approves Chipscreen Bioscience’s Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma
National Medical Products Administration (NMPA) Approves Chipscreen Bioscience’s Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma

2024.04.25

“Chinese Researchers + Innovative Drugs” Shine on the Global Stage | Chidamide Clinical Studies Selected for 2024 ASCO LBA and Multiple Presentations
“Chinese Researchers + Innovative Drugs” Shine on the Global Stage | Chidamide Clinical Studies Selected for 2024 ASCO LBA and Multiple Presentations

2024.03.18

Wang Cheng, Secretary of the Party Committee and Chairman of Sichuan Energy Investment, and his team visited Chipscreen Biosciences for inspection and survey
Wang Cheng, Secretary of the Party Committee and Chairman of Sichuan Energy Investment, and his team visited Chipscreen Biosciences for inspection and survey

2024.03.18

Positive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis
Positive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis

2024.03.04

CAPability-01 study was published in Nature Medicine! Chidamide + sintilimab + bevacizumab explored "no man's land" for the treatment of intestinal cancer
CAPability-01 study was published in Nature Medicine! Chidamide + sintilimab + bevacizumab explored "no man's land" for the treatment of intestinal cancer

2021.12.01

Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan
Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan

2021.04.16

Chipscreen received a Phase 1b/2 clinical trial of Chiauranib/CS2164 IND clearance from the US Food and Drug Administration (FDA)
Chipscreen received a Phase 1b/2 clinical trial of Chiauranib/CS2164 IND clearance from the US Food and Drug Administration (FDA)

Media contact

Media contact

（+86）0755-36993500
pr@chipscreen.com